Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
J Cataract Refract Surg ; 24(7): 961-3, 1998 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-9682118

RESUMEN

PURPOSE: To determine the safety and efficacy of intracameral injections of unpreserved lidocaine to reduce intraocular sensation. SETTING: Carolina Eye Associates, Southern Pines, North Carolina, USA. METHODS: In this prospective study, 100 patients having phacoemulsification under topical anesthesia were randomly assigned to receive an intracameral injection of unpreserved lidocaine (0.5 cc of a 1% unpreserved solution) or balanced salt solution. RESULTS: Ninety-three patients completed the study. There were no significant between-group differences in cell density parameters or Kowa laser flare-cell meter measurements. Seventy-eight percent of lidocaine patients and 56% of controls reported no sensation (P = .048, Fisher's exact test). CONCLUSION: Intracameral injections of unpreserved lidocaine safely and effectively reduced intraocular sensation during phacoemulsification.


Asunto(s)
Anestesia Local/métodos , Anestésicos Locales/administración & dosificación , Cámara Anterior/efectos de los fármacos , Lidocaína/administración & dosificación , Facoemulsificación , Sensación/efectos de los fármacos , Anestésicos Locales/efectos adversos , Recuento de Células , Córnea/efectos de los fármacos , Humanos , Inyecciones , Soluciones Isotónicas , Lidocaína/efectos adversos , Soluciones Oftálmicas , Conservadores Farmacéuticos , Estudios Prospectivos , Seguridad , Encuestas y Cuestionarios
2.
Equine Vet J ; 24(4): 295-9, 1992 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-1499538

RESUMEN

Intakes of milk and milk nutrients were determined for 8 foals at 11-18 days of age and for 10 foals at 30-44 days and 60-74 days of age while sucking grazing mares. Water intakes (sources other than milk) of the foals were determined at 30-44 days and 60-74 days of age. Five of the 10 mares were fed a protein supplement (24% crude protein) in addition to grazing during the stud season. The protein supplement did not influence foal intakes of milk and milk nutrients, milk composition, weight gains of the mares or the growth rate of the foals. Foal milk intakes increased (P less than 0.05) from 16.9 kg/day at 11-18 days to 18.1 kg/day at 60-74 days of age. The water intakes of the foals increased (P less than 0.01) from 3.9 kg/day at 30-44 days to 5.5 kg/day at 60-74 days of age. Total fluid intakes per kg foal liveweight were 246, 202 and 172 g at 11-18, 30-44 and 60-74 days of age, respectively. For each kg of weight gain, foals consumed 12.8, 15.7 and 16.4 kg milk at 11-18, 30-44 and 60-74 days of age. Stage of lactation had a significant effect on the total solids, lactose and protein content of milk. The fat and gross energy content of milk remained constant.


Asunto(s)
Animales Lactantes/fisiología , Ingestión de Líquidos , Ingestión de Alimentos , Caballos/fisiología , Leche , Alimentación Animal , Animales , Animales Lactantes/crecimiento & desarrollo , Peso Corporal , Proteínas en la Dieta/administración & dosificación , Femenino , Alimentos Fortificados , Caballos/crecimiento & desarrollo , Lactancia , Leche/análisis , Aumento de Peso
3.
Cancer ; 62(10): 2098-104, 1988 Nov 15.
Artículo en Inglés | MEDLINE | ID: mdl-3179922

RESUMEN

Three hundred ten patients with Stage II or Stage III breast cancer were entered on an adjuvant protocol consisting of a combination of 5-fluorouracil, doxorubicin, cyclophosphamide, vincristine, and prednisone (FACVP). In the second phase of the study, patients with estrogen receptor-negative tumors received sequential courses of methotrexate and vinblastine. Other patients, who were estrogen receptor-positive or unknown, were randomized to receive either tamoxifen alone or tamoxifen plus methotrexate and vinblastine. All therapy was completed within 1 year. The estimated disease-free rate at 5 years was 68% among patients with Stage II disease and 52% for patients who had Stage III disease. Among patients with estrogen receptor-positive tumors, disease-free survival was significantly prolonged in patients who received methotrexate and vinblastine in addition to tamoxifen (P = 0.04). However, this difference was less pronounced when all randomized patients (including those whose estrogen receptor status was unknown) were included in the comparison. Although most patients experienced moderate to severe granulocytopenia, infectious complications were infrequent. One patient died of septicemia. Congestive heart failure developed in two patients, one of whom had a history of myocardial infarction and congestive heart failure.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Protocolos de Quimioterapia Combinada Antineoplásica/efectos adversos , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Terapia Combinada , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Estudios de Seguimiento , Humanos , Metástasis Linfática , Menopausia , Persona de Mediana Edad , Estadificación de Neoplasias , Prednisona/administración & dosificación , Receptores de Estrógenos/análisis , Vincristina/administración & dosificación
4.
Cancer Res ; 46(9): 4576-81, 1986 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-3731111

RESUMEN

In a V-2 model of solitary hepatic metastasis, residual tumor was histologically identified in the treatment field in only three of 14 (21%) animals subjected to microsphere embolization of tumor arterioles plus focal (43 degrees C, 40 min) hyperthermia compared with seven of ten (70%) subjected to focal (43 degrees C, 40 min) hyperthermia alone (P less than or equal to 0.05), five of seven (71%) (P less than or equal to 0.05) treated by occlusion plus sham heating, and five of five (100%) (P less than or equal to 0.01) sham-treated controls. Prior occlusion tended to reduce the radiofrequency power required for heat up and steady-state temperature maintenance of tumors (P less than or equal to 0.09 and P less than or equal to 0.06, respectively) and reduced the cooling rate after heating compared to unoccluded tumors (P less than or equal to 0.02) but did not affect mean time to temperature, maximum and minimum temperature measured at the tumor-normal tissue interface, and animal core temperature compared with that of the hyperthermia alone treatment group. In ten other animals with hepatic V-2 tumors of comparable size subjected to focal hyperthermia plus or minus arteriolar embolization, temperatures were continuously monitored at four additional intratumor sites in a fixed geometric orientation around the heating probe. No significant differences were noted in maximum and minimum temperatures in comparably oriented probes over a 40-min heating period between the hyperthermia and the occlusion-hyperthermia treatment groups. In five other animals with solitary V-2 hepatic implants, comparable microembolization plus or minus focal tumor heating to 43 degrees C, 40 min, did not significantly reduce tumor interstitial pH compared with pretreatment values. This study reproduces previously observed synergism between arteriolar embolization and hyperthermia but suggests the mechanism may be unrelated to observable differences in intratumor pH and thermal profile and may result from other mechanisms, perhaps by mimicking the angioocclusive effects of hyperthermia itself.


Asunto(s)
Neoplasias Hepáticas/secundario , Neoplasias Experimentales/terapia , Animales , Embolización Terapéutica , Concentración de Iones de Hidrógeno , Hipertermia Inducida , Neoplasias Hepáticas/irrigación sanguínea , Conejos
5.
Invest Radiol ; 20(7): 736-41, 1985 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-4066244

RESUMEN

Utilizing technology recently developed in our laboratory, hypervascular, heat-resistant V-2 tumors growing in the rabbit hindlimb were variously subjected to selective vascular occlusion by embolization with Dextran M microspheres and focal hyperthermia to minimum intratumor temperatures of 43 degrees C X 40 minutes (OH), focal 43 degrees C X 40 minutes hyperthermia alone (H), selective occlusion plus sham hyperthermia (O), and sham treatment. Regional toxicity observed consisted of skin burns and muscle fibrosis in the H and OH groups and peripheral embolization in the O alone group. Tumors subjected to a single OH treatment had significantly reduced growth rate over a 28-day period of observation compared with all other treatment groups and sham-treated controls (P less than or equal to .05). Our findings suggest that the combination of selective vascular embolization and focused hyperthermia may be useful in therapy of hypervascular, heat-resistant human tumors in anatomic locations where selective occlusion and relatively intense focal heating can be performed. The regional toxicity encountered in this model reemphasizes the need for extensive thermal mapping over the heated region.


Asunto(s)
Embolización Terapéutica , Hipertermia Inducida , Neoplasias Experimentales/terapia , Animales , Miembro Posterior , Masculino , Microesferas , Neoplasias Experimentales/patología , Conejos
6.
Invest Radiol ; 20(2): 159-65, 1985.
Artículo en Inglés | MEDLINE | ID: mdl-3988467

RESUMEN

An animal model of partial hepatic artery occlusion and radiofrequency (RF)-induced hepatic hyperthermia was developed in the New Zealand white rabbit. Seventy-seven percent (10/13) of animals survived partial hepatic artery occlusion, 82% (41/50) survived RF-induced hepatic hyperthermia, and 66% (24/36) survived combined occlusion-hyperthermia. Mesenteric infarction secondary to inadvertent embolization of intestinal arteries was the principal cause of death in animals undergoing partial hepatic artery occlusion. Extrahepatic thermal toxicity appeared to be the major cause of death in animals subjected to hepatic hyperthermia or occlusion hyperthermia although some animals showed evidence of hepatic necrosis as well. Recent developments in our laboratory hold the promise that extrahepatic thermal toxicity can be eliminated by selectively focusing heat into the liver allowing exploration of the efficacy of occlusion-hyperthermia in controlling VX-2 tumors implanted in the rabbit liver.


Asunto(s)
Embolización Terapéutica/efectos adversos , Hipertermia Inducida/efectos adversos , Neoplasias Hepáticas/terapia , Animales , Terapia Combinada , Arteria Hepática , Masculino , Conejos
7.
Med Instrum ; 18(4): 220-3, 1984.
Artículo en Inglés | MEDLINE | ID: mdl-6493095

RESUMEN

Critical modifications have been made in the grounded elements of a previously reported hybrid radiofrequency heating system with inductive, capacitive, and grounded elements designed for deep focal heating. These modifications facilitate introduction of the ground probe, the single invasive element of the system, into animals and humans. The modified grounded elements also enable monitoring and optimization of ground point current, thereby improving control of heating rate, and greatly increase the volume of tissue that can be heated using a single invasive grounding element, embedded in a lossy dielectric field in the near field of the radiofrequency hyperthermia system.


Asunto(s)
Hipertermia Inducida/instrumentación , Ondas de Radio , Termómetros
8.
Cancer ; 53(3): 384-9, 1984 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-6362814

RESUMEN

Between May 1977 and April 1980, 238 patients with operable breast cancer were treated with adjuvant fluorouracil, doxorubicin, and cyclophosphamide (FAC) chemotherapy. All patients were randomized to receive FAC alone or FAC with nonspecific immunotherapy with Bacillus Calmette-Guerin (BCG) vaccine. A randomization for routine postoperative irradiation was included in the study in May 1978. At the median follow-up of 33 months, 53 patients had developed recurrent disease. Up to the present time, there have been no significant differences in the disease-free survival of patients treated with FAC alone from those treated with FAC + BCG (P = 0.21). The disease-free survival for patients treated with and without routine postoperative irradiation was similar (P = 0.99). Disease-free survival of premenopausal and postmenopausal women was similar. The overall estimate of disease-free survival was 72% at 3 years.


Asunto(s)
Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Vacuna BCG/uso terapéutico , Neoplasias de la Mama/terapia , Neoplasias de la Mama/tratamiento farmacológico , Neoplasias de la Mama/radioterapia , Neoplasias de la Mama/cirugía , Ensayos Clínicos como Asunto , Terapia Combinada , Ciclofosfamida/administración & dosificación , Doxorrubicina/administración & dosificación , Femenino , Fluorouracilo/administración & dosificación , Humanos , Persona de Mediana Edad , Estudios Prospectivos , Distribución Aleatoria
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA